Drug Shortage Report for TEVA-IRBESARTAN
| Report ID | 94369 |
| Drug Identification Number | 02316404 |
| Brand name | TEVA-IRBESARTAN |
| Common or Proper name | IRBESARTAN |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | IRBESARTAN |
| Strength(s) | 150MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 100 |
| ATC code | C09CA |
| ATC description | ANGIOTENSIN II ANTAGONISTS, PLAIN |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2019-09-18 |
| Estimated end date | 2021-09-30 |
| Actual end date | 2021-09-09 |
| Shortage status | Resolved |
| Updated date | 2021-09-10 |
| Company comments | Will continue to allocate until regular supply can be restored (TBA) Allocating 100% of Teva market share from July to August. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v21 | 2020-04-09 | English | Compare |
| v20 | 2020-04-02 | French | Compare |
| v19 | 2020-04-02 | English | Compare |
| v18 | 2020-02-13 | French | Compare |
| v17 | 2020-02-13 | English | Compare |
| v16 | 2020-01-24 | French | Compare |
| v15 | 2020-01-24 | English | Compare |
| v14 | 2019-12-19 | French | Compare |
| v13 | 2019-12-19 | English | Compare |
| v12 | 2019-12-05 | French | Compare |
| v11 | 2019-12-05 | English | Compare |
| v10 | 2019-11-28 | French | Compare |
| v9 | 2019-11-28 | English | Compare |
| v8 | 2019-10-24 | French | Compare |
| v7 | 2019-10-24 | English | Compare |
| v6 | 2019-10-17 | French | Compare |
| v5 | 2019-10-17 | English | Compare |
| v4 | 2019-09-26 | French | Compare |
| v3 | 2019-09-26 | English | Compare |
| v2 | 2019-09-19 | French | Compare |